Merck & Co Inc

NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024

MRK Articles

Apple, Disney, Merck, and Pfizer were the leading gainers among the Dow 30 stocks on Monday. Bitcoin settled up 23% after its first trading session.
The question for investors is pretty simple: 2017 was great, but what do they do for an encore in 2018?
Some down and out stocks don't always stay down, and sometimes great turnarounds and recoveries can create huge victories for opportunistic and visionary investors.
Microsoft and Vise were Wednesday's big DJIA gainers while Merck and Disney dipped the most.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
Merck, Omega Health, Cardinal Health, and Curis all posted new 52-week lows Monday.
Intel, Merck, McDonald's, and Exxon Mobil weighed on the DJIA Friday.
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
JPMorgan and Caterpillar were the leading losers among the DJIA stocks Wednesday, offset by better showings from Merck and Walmart.
Apple, General Electric, Walmart, and Merck combined to push the DJIA up a little a Friday.
The include Axalta, Baidu, Cypress Semi, Merck, Microsoft, Switch top analyst upgrades, downgrades and other research calls from Tuesday.
Monday was a relatively negative day for the markets with all of the major U.S. exchanges pulling back. Crude oil started out flat but came on strong in the afternoon. The S&P 500 sectors were...
Merck, General Electric, Macy's, and CenturyLink all posted new 52-week lows Monday.